SW
XFOR icon

SVB Wealth’s X4 Pharmaceuticals XFOR Stock Holding History

SVB Wealth’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-433
Closed -$18.1K – 834
2024
Q1 		$18.1K Buy
+433
New +$12K ﹤0.01% 846

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth's XFOR Position: Q2 2024 in Review

SVB Wealth sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 433 shares — an estimated $18.1K sold.

SVB Wealth first reported a position in XFOR in Q1 2024 and held it in 1 quarter. The position peaked at $18.1K in Q1 2024. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • SVB Wealth reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • SVB Wealth sold 433 X4 Pharmaceuticals shares in Q2 2024, an estimated $18.1K.
  • SVB Wealth first reported a position in X4 Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • SVB Wealth's X4 Pharmaceuticals position peaked at $18.1K in Q1 2024.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on SVB Wealth's 13F filing for Q2 2024, filed 6 Aug 2024.